Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis C | 32 | 2024 | 1578 | 7.860 |
Why?
|
Antiviral Agents | 39 | 2024 | 3061 | 6.140 |
Why?
|
Hepacivirus | 31 | 2023 | 1333 | 5.520 |
Why?
|
Hepatitis C, Chronic | 18 | 2023 | 1031 | 4.960 |
Why?
|
Cost-Benefit Analysis | 47 | 2024 | 5507 | 4.270 |
Why?
|
Carcinoma, Hepatocellular | 11 | 2023 | 2297 | 2.430 |
Why?
|
Quality-Adjusted Life Years | 25 | 2022 | 1724 | 2.160 |
Why?
|
Liver Diseases, Alcoholic | 3 | 2023 | 156 | 2.050 |
Why?
|
Liver Neoplasms | 11 | 2023 | 4317 | 1.930 |
Why?
|
Models, Economic | 8 | 2021 | 719 | 1.890 |
Why?
|
Markov Chains | 14 | 2021 | 971 | 1.840 |
Why?
|
Liver Transplantation | 7 | 2019 | 2317 | 1.660 |
Why?
|
Models, Theoretical | 14 | 2019 | 3561 | 1.550 |
Why?
|
Anus Neoplasms | 5 | 2024 | 329 | 1.200 |
Why?
|
Prisoners | 4 | 2019 | 310 | 1.100 |
Why?
|
Health Care Costs | 8 | 2023 | 3257 | 1.040 |
Why?
|
Mass Screening | 11 | 2024 | 5422 | 0.960 |
Why?
|
Opioid-Related Disorders | 4 | 2023 | 2135 | 0.900 |
Why?
|
End Stage Liver Disease | 2 | 2019 | 347 | 0.890 |
Why?
|
Decision Support Techniques | 6 | 2021 | 2002 | 0.820 |
Why?
|
Cost of Illness | 8 | 2024 | 1940 | 0.750 |
Why?
|
Alcohol-Related Disorders | 1 | 2023 | 235 | 0.720 |
Why?
|
Epidemics | 2 | 2023 | 513 | 0.690 |
Why?
|
Disease Transmission, Infectious | 2 | 2015 | 558 | 0.680 |
Why?
|
Papillomavirus Vaccines | 4 | 2019 | 486 | 0.660 |
Why?
|
Papillomavirus Infections | 7 | 2021 | 1600 | 0.660 |
Why?
|
Liver Cirrhosis | 8 | 2023 | 1925 | 0.630 |
Why?
|
Genotype | 9 | 2019 | 12959 | 0.630 |
Why?
|
Costs and Cost Analysis | 5 | 2017 | 1679 | 0.610 |
Why?
|
Humans | 123 | 2024 | 760261 | 0.600 |
Why?
|
Online Systems | 1 | 2018 | 181 | 0.600 |
Why?
|
Pandemics | 9 | 2024 | 8621 | 0.580 |
Why?
|
Proline | 3 | 2013 | 457 | 0.580 |
Why?
|
Hepatitis, Alcoholic | 1 | 2019 | 109 | 0.580 |
Why?
|
Chenodeoxycholic Acid | 1 | 2017 | 34 | 0.560 |
Why?
|
United States | 39 | 2024 | 72363 | 0.550 |
Why?
|
Analgesics, Opioid | 4 | 2023 | 3762 | 0.530 |
Why?
|
Feasibility Studies | 3 | 2024 | 5201 | 0.530 |
Why?
|
Chemoprevention | 1 | 2018 | 326 | 0.530 |
Why?
|
Homosexuality, Male | 4 | 2024 | 1269 | 0.520 |
Why?
|
Cholangitis | 1 | 2017 | 113 | 0.520 |
Why?
|
Waiting Lists | 2 | 2019 | 754 | 0.520 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2017 | 1628 | 0.510 |
Why?
|
Drugs, Generic | 2 | 2018 | 448 | 0.500 |
Why?
|
Liver Diseases | 2 | 2023 | 1301 | 0.490 |
Why?
|
Uridine Monophosphate | 1 | 2015 | 68 | 0.480 |
Why?
|
Carcinoma in Situ | 2 | 2017 | 796 | 0.470 |
Why?
|
Fluorenes | 1 | 2015 | 157 | 0.450 |
Why?
|
Hematologic Neoplasms | 2 | 2015 | 1899 | 0.440 |
Why?
|
Prevalence | 11 | 2024 | 15687 | 0.420 |
Why?
|
Cost Savings | 2 | 2020 | 920 | 0.400 |
Why?
|
Mass Vaccination | 1 | 2013 | 109 | 0.400 |
Why?
|
Decision Making | 5 | 2018 | 3924 | 0.400 |
Why?
|
Probability | 2 | 2022 | 2476 | 0.400 |
Why?
|
Uncertainty | 1 | 2016 | 754 | 0.380 |
Why?
|
Economics, Medical | 2 | 2022 | 112 | 0.380 |
Why?
|
Gastroenterology | 1 | 2017 | 571 | 0.370 |
Why?
|
Prisons | 4 | 2023 | 170 | 0.370 |
Why?
|
Drug Costs | 2 | 2018 | 1184 | 0.360 |
Why?
|
Precancerous Conditions | 1 | 2017 | 978 | 0.360 |
Why?
|
Models, Biological | 2 | 2019 | 9468 | 0.360 |
Why?
|
Hepatitis B | 3 | 2020 | 701 | 0.350 |
Why?
|
Forecasting | 4 | 2024 | 2931 | 0.350 |
Why?
|
Risk Assessment | 11 | 2020 | 24086 | 0.350 |
Why?
|
Benzimidazoles | 1 | 2015 | 858 | 0.340 |
Why?
|
Schools | 2 | 2020 | 1474 | 0.340 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2013 | 448 | 0.330 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1189 | 0.330 |
Why?
|
Public Health | 5 | 2023 | 2655 | 0.330 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 3159 | 0.320 |
Why?
|
Health Policy | 3 | 2018 | 2678 | 0.310 |
Why?
|
Spain | 2 | 2019 | 487 | 0.300 |
Why?
|
Viremia | 3 | 2023 | 708 | 0.300 |
Why?
|
Budgets | 3 | 2019 | 230 | 0.290 |
Why?
|
Middle Aged | 39 | 2024 | 220175 | 0.290 |
Why?
|
Adult | 36 | 2024 | 219847 | 0.290 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2024 | 2018 | 0.280 |
Why?
|
Incidence | 10 | 2024 | 21378 | 0.280 |
Why?
|
Atrial Fibrillation | 2 | 2022 | 5201 | 0.270 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 2696 | 0.270 |
Why?
|
Life Expectancy | 3 | 2019 | 1249 | 0.270 |
Why?
|
Female | 46 | 2024 | 391011 | 0.260 |
Why?
|
alpha-Fetoproteins | 2 | 2023 | 222 | 0.260 |
Why?
|
Male | 38 | 2024 | 359413 | 0.250 |
Why?
|
Hematologic Tests | 2 | 2023 | 238 | 0.250 |
Why?
|
Models, Statistical | 6 | 2024 | 5073 | 0.240 |
Why?
|
Treatment Outcome | 14 | 2021 | 64947 | 0.230 |
Why?
|
HIV Infections | 6 | 2024 | 17159 | 0.230 |
Why?
|
Moldova | 1 | 2023 | 14 | 0.230 |
Why?
|
Stroke | 2 | 2022 | 9945 | 0.210 |
Why?
|
Mammography | 6 | 2014 | 2452 | 0.210 |
Why?
|
Glucagon-Like Peptides | 1 | 2024 | 159 | 0.210 |
Why?
|
Basic Reproduction Number | 1 | 2022 | 35 | 0.200 |
Why?
|
Gastroplasty | 1 | 2024 | 157 | 0.200 |
Why?
|
Georgia (Republic) | 1 | 2021 | 39 | 0.200 |
Why?
|
Influenza, Human | 1 | 2013 | 1532 | 0.200 |
Why?
|
Alcohol Drinking | 3 | 2022 | 4012 | 0.200 |
Why?
|
Computer Simulation | 5 | 2020 | 6210 | 0.200 |
Why?
|
Aged | 25 | 2024 | 168995 | 0.190 |
Why?
|
Rwanda | 1 | 2024 | 662 | 0.190 |
Why?
|
Substance Abuse, Intravenous | 2 | 2023 | 529 | 0.180 |
Why?
|
Microbiological Techniques | 1 | 2021 | 98 | 0.180 |
Why?
|
Reproducibility of Results | 4 | 2020 | 20048 | 0.180 |
Why?
|
Naloxone | 1 | 2023 | 369 | 0.180 |
Why?
|
Brugada Syndrome | 1 | 2021 | 95 | 0.180 |
Why?
|
Adenosine Monophosphate | 1 | 2022 | 283 | 0.170 |
Why?
|
Economics, Pharmaceutical | 1 | 2020 | 88 | 0.170 |
Why?
|
Alanine | 1 | 2022 | 607 | 0.170 |
Why?
|
Logistic Models | 4 | 2014 | 13311 | 0.170 |
Why?
|
Indians, North American | 1 | 2023 | 355 | 0.160 |
Why?
|
Disease Progression | 4 | 2017 | 13505 | 0.160 |
Why?
|
Sentinel Surveillance | 1 | 2021 | 293 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2017 | 9274 | 0.160 |
Why?
|
Hyperthyroidism | 1 | 2021 | 291 | 0.160 |
Why?
|
Administration, Oral | 2 | 2017 | 4044 | 0.160 |
Why?
|
Pennsylvania | 3 | 2016 | 615 | 0.160 |
Why?
|
Tissue Donors | 2 | 2018 | 2314 | 0.160 |
Why?
|
Systems Analysis | 1 | 2019 | 169 | 0.160 |
Why?
|
Quarantine | 1 | 2020 | 176 | 0.160 |
Why?
|
Contact Tracing | 1 | 2020 | 268 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 218 | 0.150 |
Why?
|
Pakistan | 1 | 2019 | 307 | 0.150 |
Why?
|
Electric Countershock | 1 | 2021 | 537 | 0.150 |
Why?
|
Papillomaviridae | 3 | 2021 | 1117 | 0.150 |
Why?
|
France | 1 | 2019 | 511 | 0.150 |
Why?
|
Population Surveillance | 2 | 2020 | 2609 | 0.150 |
Why?
|
Bariatric Surgery | 2 | 2019 | 1006 | 0.150 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5396 | 0.150 |
Why?
|
Comparative Effectiveness Research | 2 | 2021 | 718 | 0.150 |
Why?
|
Operations Research | 1 | 2017 | 22 | 0.140 |
Why?
|
Genital Diseases, Male | 1 | 2017 | 83 | 0.140 |
Why?
|
India | 3 | 2021 | 2346 | 0.140 |
Why?
|
Cohort Studies | 6 | 2018 | 41317 | 0.140 |
Why?
|
Italy | 1 | 2019 | 840 | 0.140 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39254 | 0.140 |
Why?
|
Germany | 1 | 2019 | 875 | 0.140 |
Why?
|
Policy | 1 | 2020 | 511 | 0.140 |
Why?
|
Carbamates | 1 | 2018 | 192 | 0.140 |
Why?
|
Ethanol | 1 | 2023 | 1323 | 0.140 |
Why?
|
Pharyngeal Diseases | 1 | 2017 | 134 | 0.140 |
Why?
|
Transportation of Patients | 2 | 2015 | 176 | 0.130 |
Why?
|
Vaccination | 2 | 2019 | 3360 | 0.130 |
Why?
|
Genital Diseases, Female | 1 | 2017 | 191 | 0.130 |
Why?
|
Dengue | 1 | 2019 | 255 | 0.130 |
Why?
|
Medicaid | 3 | 2019 | 2811 | 0.130 |
Why?
|
Health Priorities | 1 | 2019 | 376 | 0.130 |
Why?
|
Diagnostic Tests, Routine | 1 | 2022 | 785 | 0.130 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2021 | 464 | 0.130 |
Why?
|
Interferon-alpha | 3 | 2015 | 919 | 0.130 |
Why?
|
Obesity, Morbid | 2 | 2017 | 1287 | 0.130 |
Why?
|
Aged, 80 and over | 10 | 2020 | 58947 | 0.130 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2015 | 64 | 0.130 |
Why?
|
Japan | 1 | 2020 | 1369 | 0.130 |
Why?
|
Postoperative Complications | 1 | 2018 | 15680 | 0.130 |
Why?
|
Mouth Diseases | 1 | 2017 | 238 | 0.120 |
Why?
|
Breast Neoplasms | 7 | 2019 | 21065 | 0.120 |
Why?
|
Fibrosis | 1 | 2022 | 2042 | 0.120 |
Why?
|
World Health Organization | 2 | 2018 | 1319 | 0.120 |
Why?
|
Regional Health Planning | 1 | 2015 | 96 | 0.120 |
Why?
|
Thyroidectomy | 1 | 2021 | 903 | 0.120 |
Why?
|
Time | 1 | 2017 | 545 | 0.120 |
Why?
|
Elasticity Imaging Techniques | 1 | 2020 | 389 | 0.120 |
Why?
|
Decision Making, Computer-Assisted | 2 | 2012 | 146 | 0.120 |
Why?
|
Communicable Disease Control | 1 | 2021 | 844 | 0.120 |
Why?
|
Young Adult | 6 | 2024 | 58673 | 0.120 |
Why?
|
Nutrition Surveys | 2 | 2019 | 1727 | 0.120 |
Why?
|
Time Factors | 8 | 2021 | 40133 | 0.120 |
Why?
|
Gadolinium DTPA | 3 | 2023 | 826 | 0.110 |
Why?
|
Sensitivity and Specificity | 8 | 2023 | 14656 | 0.110 |
Why?
|
Thyroid Nodule | 1 | 2021 | 760 | 0.110 |
Why?
|
Guideline Adherence | 2 | 2021 | 2283 | 0.110 |
Why?
|
Alcoholism | 1 | 2023 | 1961 | 0.110 |
Why?
|
Suicide | 1 | 2023 | 1599 | 0.100 |
Why?
|
Linear Models | 1 | 2022 | 5876 | 0.100 |
Why?
|
Folic Acid | 1 | 2019 | 1309 | 0.100 |
Why?
|
RNA | 1 | 2022 | 2721 | 0.100 |
Why?
|
Risk Factors | 12 | 2024 | 74269 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 10340 | 0.100 |
Why?
|
Defibrillators, Implantable | 1 | 2021 | 1499 | 0.100 |
Why?
|
Biopsy, Needle | 1 | 2017 | 1633 | 0.100 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15827 | 0.100 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2015 | 385 | 0.100 |
Why?
|
Hospital Costs | 1 | 2017 | 976 | 0.090 |
Why?
|
Quality of Life | 5 | 2024 | 13300 | 0.090 |
Why?
|
Communicable Diseases | 1 | 2019 | 879 | 0.090 |
Why?
|
Health Expenditures | 1 | 2023 | 2359 | 0.090 |
Why?
|
Immunization Programs | 1 | 2013 | 268 | 0.090 |
Why?
|
Neoplasms, Second Primary | 1 | 2018 | 1060 | 0.090 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3215 | 0.090 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 7803 | 0.090 |
Why?
|
Occupational Exposure | 1 | 2020 | 1809 | 0.090 |
Why?
|
HIV | 1 | 2017 | 1579 | 0.090 |
Why?
|
Hemorrhage | 1 | 2022 | 3604 | 0.090 |
Why?
|
Mental Health | 2 | 2023 | 3206 | 0.090 |
Why?
|
Trauma Centers | 1 | 2015 | 934 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4900 | 0.080 |
Why?
|
Triage | 1 | 2015 | 982 | 0.080 |
Why?
|
Gastric Bypass | 1 | 2017 | 826 | 0.080 |
Why?
|
Preoperative Care | 1 | 2017 | 2255 | 0.070 |
Why?
|
Disease Management | 1 | 2018 | 2508 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2021 | 2332 | 0.070 |
Why?
|
Retrospective Studies | 9 | 2023 | 80301 | 0.070 |
Why?
|
Prospective Studies | 4 | 2021 | 54263 | 0.070 |
Why?
|
Acute Disease | 1 | 2018 | 7268 | 0.070 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 938 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1094 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3310 | 0.070 |
Why?
|
Anti-Retroviral Agents | 1 | 2016 | 1780 | 0.070 |
Why?
|
SEER Program | 3 | 2018 | 1532 | 0.070 |
Why?
|
Survival Analysis | 1 | 2019 | 10185 | 0.070 |
Why?
|
Age Factors | 2 | 2020 | 18415 | 0.060 |
Why?
|
Dietary Supplements | 1 | 2019 | 3389 | 0.060 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 1401 | 0.060 |
Why?
|
Primary Health Care | 2 | 2021 | 4649 | 0.060 |
Why?
|
Life Style | 1 | 2017 | 3888 | 0.060 |
Why?
|
Medicare | 2 | 2022 | 6771 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10829 | 0.060 |
Why?
|
ROC Curve | 2 | 2009 | 3568 | 0.060 |
Why?
|
Regression Analysis | 2 | 2014 | 6361 | 0.060 |
Why?
|
Liver | 1 | 2020 | 7512 | 0.060 |
Why?
|
Washington | 2 | 2015 | 312 | 0.060 |
Why?
|
Contrast Media | 3 | 2023 | 5301 | 0.060 |
Why?
|
Weight Loss | 3 | 2024 | 2683 | 0.060 |
Why?
|
Registries | 4 | 2018 | 8449 | 0.060 |
Why?
|
Graft Rejection | 1 | 2017 | 4423 | 0.060 |
Why?
|
Breast | 1 | 2012 | 1980 | 0.060 |
Why?
|
Adolescent | 7 | 2018 | 87747 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7468 | 0.050 |
Why?
|
Pattern Recognition, Automated | 1 | 2009 | 988 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2019 | 3763 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11064 | 0.050 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2023 | 3764 | 0.050 |
Why?
|
Calibration | 2 | 2019 | 816 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Chronic Disease | 1 | 2018 | 9283 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2009 | 1215 | 0.050 |
Why?
|
Critical Illness | 1 | 2015 | 2709 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2015 | 3598 | 0.050 |
Why?
|
Seroepidemiologic Studies | 1 | 2023 | 393 | 0.050 |
Why?
|
Malaysia | 1 | 2021 | 107 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 29636 | 0.050 |
Why?
|
Ribavirin | 2 | 2013 | 396 | 0.050 |
Why?
|
Software | 1 | 2015 | 4420 | 0.050 |
Why?
|
Organizations, Nonprofit | 1 | 2021 | 105 | 0.050 |
Why?
|
Algorithms | 3 | 2017 | 13967 | 0.050 |
Why?
|
Societies | 1 | 2021 | 108 | 0.050 |
Why?
|
North America | 1 | 2024 | 1282 | 0.050 |
Why?
|
HIV-1 | 1 | 2017 | 6850 | 0.040 |
Why?
|
Ohio | 1 | 2020 | 333 | 0.040 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 2019 | 39 | 0.040 |
Why?
|
Albumins | 1 | 2022 | 577 | 0.040 |
Why?
|
Bayes Theorem | 2 | 2022 | 2325 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2017 | 5324 | 0.040 |
Why?
|
Human papillomavirus 18 | 1 | 2019 | 126 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2128 | 0.040 |
Why?
|
Georgia | 1 | 2018 | 185 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2021 | 582 | 0.040 |
Why?
|
New York | 1 | 2020 | 874 | 0.040 |
Why?
|
Vaginal Neoplasms | 1 | 2018 | 105 | 0.040 |
Why?
|
Criminal Law | 1 | 2018 | 98 | 0.040 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 266 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36247 | 0.040 |
Why?
|
Polyethylene Glycols | 2 | 2013 | 1188 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2018 | 507 | 0.040 |
Why?
|
Homosexuality | 1 | 2017 | 261 | 0.030 |
Why?
|
Penile Neoplasms | 1 | 2018 | 162 | 0.030 |
Why?
|
Vitamin B Complex | 1 | 2019 | 297 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 25928 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 4044 | 0.030 |
Why?
|
Risk | 2 | 2020 | 9629 | 0.030 |
Why?
|
National Institute on Alcohol Abuse and Alcoholism (U.S.) | 1 | 2015 | 10 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2020 | 495 | 0.030 |
Why?
|
Universities | 1 | 2021 | 983 | 0.030 |
Why?
|
Vulvar Neoplasms | 1 | 2018 | 265 | 0.030 |
Why?
|
Bed Occupancy | 1 | 2015 | 38 | 0.030 |
Why?
|
Intracranial Hemorrhages | 1 | 2021 | 844 | 0.030 |
Why?
|
Homocysteine | 1 | 2019 | 640 | 0.030 |
Why?
|
Football | 1 | 2021 | 502 | 0.030 |
Why?
|
Body Mass Index | 3 | 2017 | 12901 | 0.030 |
Why?
|
Social Class | 1 | 2022 | 2005 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3106 | 0.030 |
Why?
|
Suicidal Ideation | 1 | 2023 | 1435 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2013 | 6543 | 0.030 |
Why?
|
Portugal | 1 | 2013 | 90 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1395 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15740 | 0.030 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2018 | 491 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15273 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 6499 | 0.030 |
Why?
|
Health Status Disparities | 1 | 2024 | 1819 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2017 | 510 | 0.030 |
Why?
|
Sex Distribution | 1 | 2017 | 2295 | 0.030 |
Why?
|
Drug Combinations | 1 | 2018 | 2024 | 0.030 |
Why?
|
Computational Biology | 1 | 2024 | 3504 | 0.020 |
Why?
|
Patient Care Team | 1 | 2023 | 2510 | 0.020 |
Why?
|
Income | 1 | 2020 | 1876 | 0.020 |
Why?
|
Recovery of Function | 1 | 2021 | 2982 | 0.020 |
Why?
|
Reoperation | 1 | 2021 | 4292 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 1374 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2557 | 0.020 |
Why?
|
Obesity | 2 | 2024 | 12915 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3381 | 0.020 |
Why?
|
Insurance, Health | 1 | 2021 | 2500 | 0.020 |
Why?
|
Electrocardiography | 1 | 2021 | 6413 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2017 | 2080 | 0.020 |
Why?
|
Developing Countries | 1 | 2020 | 2880 | 0.020 |
Why?
|
Survivors | 1 | 2018 | 2367 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8805 | 0.020 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 709 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2776 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12806 | 0.010 |
Why?
|
Mortality | 1 | 2015 | 2916 | 0.010 |
Why?
|
Depression | 1 | 2023 | 8033 | 0.010 |
Why?
|
Patient Discharge | 1 | 2015 | 3475 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2014 | 1927 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11141 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6775 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14482 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2013 | 12412 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12968 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2010 | 8945 | 0.010 |
Why?
|